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Introduction. D90 of 145Gy was adopted as the standard for I-125 seed implants. Dose-escalation in EBRT beneﬁt is widely
demonstrated for prostate cancer.
Objective. The aim of this dose escalating study (from D90>145Gy to D90>160Gy) is to analyze the biochemical recurrence-free
survival (bRFS) and toxicity proﬁle of prostate cancer patients treated with I-125 seeds implant.
Materials and methods. From January 08 to December 10, 219 low-risk and one factor intermediate-risk patients were chosen for
160Gy I-125 therapies. Previous MRI, urinary ﬂowmetry and IPSS questionnaire were realized. Using real-time intraoperative
interactive planning, prescribed dose was 160Gy, keeping the same urethral and rectal constraints as when 144Gy was the
prescribed dose. One month post-implant CT and MRI were realized for post-planning. Median age was 68 years old (range
41–79), median PSA 7.7ng/ml (range 2–33) and median Gleason 6. 79 patients were treated with hormone therapy (HT) (media
duration 4 months). Median US prostate volume was 35 cm3 (range 10–72). Retrospectively maximal acute and chronic toxicity,
using CTCv4.0 and RTOG scales, and bRFS, using Phoenix deﬁnition, were evaluated.
Results. The incidence of grade 3–4 acute toxicity was 3% (8 patients required urinary catheter because of acute retention, all
solved with medical treatment). No grade 3–4 chronic toxicity was observed. 73% of patients remained sexual function. 13 (6%)
patients presented biochemical failure. All patient with negative complementary exams (12/13) underwent to trans-perineal
prostate saturation biopsy, always, at least, 2 years after treatment. One of them presented histological failure and salvage
treatment with a new seed implant (120Gy) was done. Unique distant failure was an isolated bone metastasis treated with HT
and SBRT.
Conclusion. Dose escalation to 160Gy in I-125 prostate implants does not give rise more toxicity than 145Gy. Clinical results are
encouraging, but with a short follow-up.
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Introduction. Most recurrences alter breast conserving surgery occur within the index cuadrant despite the presence of multi-
centric cancers elsewhere in the breast. Thus, partial breast irradiation might be adequate for selected patients. High dose rate
brachytherapy (HDR-BT) is a feasible and comfortable technique for this partial approach.
Aim. After previous experience using HDR-BT as a boost, the aim of the study was to evaluate the feasibility, clinical results and
toxicity of HDR-BT delivered following the national protocol from SEOR Brachytherapy Group.
Methods. Between 2002 and 2013, 95 patients with early stage breast cancer were treated after conservative surgery with HDR-BT
using metallic needles adapted to surgical bed, with CT-based 3D dosimetry, delivering a dose of 32Gy in 8 fractions of 4Gy, as
the unique adjuvant radiation treatment.
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